Eton Pharmaceuticals (ETON) Stock Statistics & Valuation Metrics

Eton Pharmaceuticals has a market cap or net worth of $681.84M. The enterprise value is $665.15M.

Eton Pharmaceuticals has 27,284,490 shares outstanding. The number of shares has decreased by -2.65% in one year.

Eton Pharmaceuticals’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is 0.12%.

The current PE Ratio of Eton Pharmaceuticals is ―. Eton Pharmaceuticals’s PEG ratio is -7.42.

In the last 12 months, Eton Pharmaceuticals had revenue of 79.95M and earned -4.60M in profits. Earnings per share was -0.17.

In the last 12 months, operating cash flow was 0.00 and capital expenditures -333.00K, giving a free cash flow of -333.00K billion.

Eton Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Eton Pharmaceuticals upcoming earnings date is May 7, 2026, TBA (Confirmed).

Eton Pharmaceuticals as a current ratio of 1.57, with Debt / Equity ratio of 35.36%

In the past 12 months, Eton Pharmaceuticals has paid 43.00K in taxes.

Eton Pharmaceuticals EV to EBITDA ratio is 111.78, with an EV/FCF ratio of 45.15.

Eton Pharmaceuticals has $25.94M in cash and marketable securities with $9.25M in debt, giving a net cash position of $16.69M billion.

Gross margin is 53.46%, with operating margin of 0.09%, and net profit margin of -5.75%.

The average price target for Eton Pharmaceuticals is $39.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy